Page last updated: 2024-08-23

raloxifene hydrochloride and charybdotoxin

raloxifene hydrochloride has been researched along with charybdotoxin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asakura, M; Asanuma, H; Hori, M; Kitakaze, M; Liao, Y; Mori, H; Node, K; Ogita, H; Sanada, S; Shinozaki, Y; Takashima, S	1
Chan, YC; Chen, ZY; Huang, Y; Lau, CW; Leung, FP; Tian, XY; Tsang, SY; Wong, WT; Yao, X; Yung, LM	1

Other Studies

2 other study(ies) available for raloxifene hydrochloride and charybdotoxin

Article	Year
Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. Journal of the American College of Cardiology, 2002, Sep-04, Volume: 40, Issue:5 Topics: Animals; Charybdotoxin; Dogs; Enzyme Inhibitors; Mitogen-Activated Protein Kinase Kinases; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Peroxidase; Potassium Channels, Calcium-Activated; Raloxifene Hydrochloride; Reperfusion Injury; Selective Estrogen Receptor Modulators	2002
Therapeutically relevant concentrations of raloxifene dilate pressurized rat resistance arteries via calcium-dependent endothelial nitric oxide synthase activation. Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:5 Topics: Androstadienes; Animals; Apamin; Blood Pressure; Calcium Signaling; Charybdotoxin; Chromones; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; In Vitro Techniques; Male; Mesenteric Arteries; Morpholines; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Ovariectomy; Phosphorylation; Potassium Channel Blockers; Protein Kinase Inhibitors; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors; Vascular Resistance; Vasodilation; Vasodilator Agents; Wortmannin	2010

Article

Year

Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart.

Journal of the American College of Cardiology, 2002, Sep-04, Volume: 40, Issue:5

Topics: Animals; Charybdotoxin; Dogs; Enzyme Inhibitors; Mitogen-Activated Protein Kinase Kinases; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Peroxidase; Potassium Channels, Calcium-Activated; Raloxifene Hydrochloride; Reperfusion Injury; Selective Estrogen Receptor Modulators

2002

Therapeutically relevant concentrations of raloxifene dilate pressurized rat resistance arteries via calcium-dependent endothelial nitric oxide synthase activation.

Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:5

Topics: Androstadienes; Animals; Apamin; Blood Pressure; Calcium Signaling; Charybdotoxin; Chromones; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; In Vitro Techniques; Male; Mesenteric Arteries; Morpholines; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Ovariectomy; Phosphorylation; Potassium Channel Blockers; Protein Kinase Inhibitors; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors; Vascular Resistance; Vasodilation; Vasodilator Agents; Wortmannin

2010